Ilsung Is Co., Ltd.

A003120

KR7003120003

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 03:30:00 16/05/2024 am IST			5-day change	1st Jan Change
19,600 ^KRW	-0.56%		-1.21%	-17.12%

2023	Ilsung Pharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Tranche Update on Ilsung Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on February 13, 2023.	CI

Tranche Update on Ilsung Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on February 9, 2022.

May 10, 2022 at 11:53 am IST

From February 10, 2022 to May 9, 2022, the company has repurchased 50,935 shares, representing 3.32% for KRW 4,220.26 million. With this, the company has completed the repurchase of 50,935 shares, representing 3.32% for KRW 4,220.26 million under the buyback announced on February 9, 2022.

Latest news about Ilsung Is Co., Ltd.

Ilsung Pharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Tranche Update on Ilsung Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on February 13, 2023.	11/23/11	CI
Tranche Update on Ilsung Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on February 13, 2023.	11/23/11	CI
Ilsung Pharmaceuticals Co., Ltd.'s Equity Buyback announced on February 13, 2023, has expired with 598,487 shares, representing 29.77% for KRW 14,994.85 million.	11/23/11	CI
Tranche Update on Ilsung Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on February 13, 2023.	15/23/15	CI
Ilsung Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
Ilsung Pharmaceuticals Co., Ltd. announces an Equity Buyback for KRW 15,000 million worth of its shares.	13/23/13	CI
Ilsung Pharmaceuticals Co., Ltd. authorizes a Buyback Plan.	13/23/13	CI
Ilsung Pharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI
Tranche Update on Ilsung Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on February 9, 2022.	10/22/10	CI
Ilsung Pharmaceuticals Co. Ltd.’s Equity Buyback announced on February 9, 2022, has expired with 50,935 shares, representing 3.32% for KRW 4,220.26 million.	09/22/09	CI
Ilsung Pharmaceuticals Co., Ltd. announces an Equity Buyback for 53,200 shares.	09/22/09	CI
Ilsung Pharmaceuticals Co., Ltd. authorizes a Buyback Plan.	09/22/09	CI
Cheil Industries Inc. completed the acquisition of Samsung C&T Corporation from a group of shareholders.	31/15/31	CI
Ilsung Seeks To Sell Stake In Samsung C&T	07/15/07	CI
Samsung C&T : Proxy advisor urges Samsung C&T holders to reject $8 billion merger	02/15/02	RE
Samsung C&T : Cheil, pitching $8 billion merger, pledges higher returns	30/15/30	RE
Ilsung Pharmaceuticals Co. Ltd.(KOSE:A003120) added to Russell Global Index	29/15/29	CI
Cheil Industries Inc. agreed to acquire Samsung C&T Corporation from a group of shareholders for KRW 8.4 trillion.	26/15/26	CI
Tranche Update on Ilsung Pharmaceuticals Co. Ltd.'s Equity Buyback Plan announced on October 11, 2013.	14/14/14	CI
Ilsung Pharmaceuticals Co. Ltd.’s Equity Buyback announced on October 11, 2013 has expired with 661 shares, representing 0.05% for KRW 51.45 million.	13/14/13	CI
Ilsung Pharmaceuticals Co. Ltd. authorizes a Buyback Plan.	11/13/11	CI
Ilsung Pharmaceuticals Co. Ltd. announces an Equity Buyback for 30,000 shares.	11/13/11	CI
Ilsung Pharmaceuticals Co. Ltd.'s Equity Buyback has expired	15/13/15	CI
Ilsung Pharmaceuticals Co. Ltd. announces an Equity Buyback	15/13/15	CI

Chart Ilsung Is Co., Ltd.

Duration

Period

More charts

Company Profile

Ilsung IS Co Ltd, formerly Ilsung Pharmaceutical Co Ltd, is a Korea-based company mainly engaged in the pharmaceuticals manufacture and sale business. The Companyâs products consist of penicillin antibiotics, contrast mediums, digestive drugs, cardiovascular agents, antihistamines, anti-diabetics, bone disease drugs, analgesics, muscle relaxants, anesthetics, skin disease drugs, cardiovascular drugs, psychiatry drugs, antivirals, antipyretics and others. The Company distributes its products through wholesalers, hospitals, pharmacies and others. The Company also provides consignment production services.

Sector

Pharmaceuticals

Calendar

13/11/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ILSUNG IS CO., LTD.	-17.12%	102M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.98%	43.92B
OTSUKA HOLDINGS CO., LTD.	+24.56%	23.09B
SANDOZ GROUP AG	+19.25%	15.35B
CIPLA LIMITED	+14.03%	13.61B
ZYDUS LIFESCIENCES LIMITED	+46.40%	12.02B
ONO PHARMACEUTICAL CO., LTD.	-10.14%	7B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.07%	5.6B

Generic Pharmaceuticals

Ilsung Is Co., Ltd.

Equities

A003120

KR7003120003

Pharmaceuticals

Tranche Update on Ilsung Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on February 9, 2022.

Latest news about Ilsung Is Co., Ltd.

Chart Ilsung Is Co., Ltd.

Company Profile

Income Statement Evolution

Sector Generic Pharmaceuticals